Daihan Pharmaceutical Co.Ltd (023910) — Cash Flow Quality Index
Daihan Pharmaceutical Co.Ltd (023910) has a Cash Flow Quality Index of 1.09x as of September 2025. Operating cash flow of ₩9.47 Billion exceeds net income of ₩8.72 Billion, indicating high earnings quality where cash backs reported profits. Explore 023910 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Daihan Pharmaceutical Co.Ltd Cash Flow Quality Index (2014–2024)
Historical Cash Flow Quality Index for Daihan Pharmaceutical Co.Ltd across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Daihan Pharmaceutical Co.Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Daihan Pharmaceutical Co.Ltd (2014–2024)
Year-by-year earnings quality comparison for Daihan Pharmaceutical Co.Ltd. For live market cap and the full company financial profile, see Daihan Pharmaceutical Co.Ltd (023910) market capitalisation.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.06x | ₩35.64 Billion | ₩33.76 Billion | ▼ -22.8% |
| 2023 | 1.37x | ₩38.86 Billion | ₩28.43 Billion | ▲ +17.7% |
| 2022 | 1.16x | ₩29.00 Billion | ₩24.96 Billion | ▼ -35.2% |
| 2021 | 1.79x | ₩40.62 Billion | ₩22.67 Billion | ▼ -7.4% |
| 2020 | 1.93x | ₩33.63 Billion | ₩17.38 Billion | ▲ +54.5% |
| 2019 | 1.25x | ₩35.26 Billion | ₩28.17 Billion | ▼ -20.6% |
| 2018 | 1.58x | ₩44.94 Billion | ₩28.52 Billion | ▲ +91.3% |
| 2017 | 0.82x | ₩20.45 Billion | ₩24.83 Billion | ▼ -47.9% |
| 2016 | 1.58x | ₩27.92 Billion | ₩17.66 Billion | ▲ +21.2% |
| 2015 | 1.30x | ₩17.98 Billion | ₩13.78 Billion | ▲ +43.4% |
| 2014 | 0.91x | ₩9.48 Billion | ₩10.42 Billion | — |